TILHealthcare · BiotechnologyTIL Stock Forecast: Instil Bio, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Instil Bio, Inc. hold a median 12-month price target of $7 — -5.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 8 Aug 2026 — in the lower half.
TIL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Instil Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (82): Smaller than most of the companies we track.
Momentum (14): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Instil Bio, Inc. — and when they’d sell — is the membership.
TIL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TIL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −5.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Jan 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 11 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2025 | JMP Securities | Reiterates | Market Perform | — |
| 23 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | JMP Securities | Reiterates | Market Perform | — |
| 7 Jan 2025 | Jefferies | Upgrade | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Nov 2024 | JMP Securities | Initiates | Market Perform | — |
| 17 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Sept 2024 | Baird | Reiterates | Outperform | — |
| 16 Sept 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Sept 2024 | Baird | Maintains | Outperform | — |
| 12 Sept 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TIL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Instil Bio, Inc. (TIL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.7×
- Price / sales
- —
- Price / book
- 0.5×
- EV / EBITDA
- −1.4×
Cheaper than 81% of US stocks
Cheaper than 85% of US stocks
Cheaper than 69% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 33% of US stocks
Higher than 30% of US stocks
- Return on equity
- −37.1%
- Return on assets
- −12.7%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
TIL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TIL appears on the weeks it earns a place.
Frequently asked questions about TIL stock
What is the TIL stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Instil Bio, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TIL stock a buy right now?
Of the 1 analysts covering Instil Bio, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Instil Bio, Inc. 47 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TIL?
As at 8 Aug 2026, Instil Bio, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).
Will TIL stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies -5.3% from the last close, and Ticker Nerd's factor model ranks Instil Bio, Inc. 47 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TIL stock forecast for 2030?
No analyst covering Instil Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TIL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.
How has TIL stock performed over the past year?
Instil Bio, Inc. returned -71.5% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Instil Bio, Inc. do?
Instil Bio, Inc. is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of cancer.
About Instil Bio, Inc.
Instil Bio, Inc. is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of cancer. Specializing within the pharmaceuticals and biotech sector, the company’s primary function is to research and advance next-generation immunotherapies, particularly those designed to harness and enhance patients’ own immune systems to target solid tumors. Instil Bio is notable for its work on tumor-infiltrating lymphocyte (TIL) therapies, as well as its proprietary bispecific antibody platforms. A key pipeline candidate, AXN-2510, is a PD-L1xVEGF bispecific antibody currently advancing through clinical trials, targeting relapsed or refractory solid tumors and non-small cell lung cancer (NSCLC). Founded in 2018, Instil Bio’s efforts impact the global healthcare market by seeking novel approaches to address cancers with unmet medical needs. The company’s research contributes to advancements in oncology and immunotherapy, sectors that are critical to the broader medical research and biopharmaceutical landscape. Instil Bio occupies a unique position among biotechnology peers, leveraging cutting-edge science to drive potential therapeutic breakthroughs in cancer care.
CEO Mr. Bronson Crouch · 17 employees · United States · https://instilbio.com